<DOC>
	<DOCNO>NCT02972320</DOCNO>
	<brief_summary>This study evaluate temozolomide maintain therapeutic efficacy safety extensive stage SCLC clinical benefit etoposide combine Los platinum ( EL ) scheme first line treatment .</brief_summary>
	<brief_title>Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic</brief_title>
	<detailed_description>According etoposide combine Los platinum ( EL ) plan administration , every cycle 21 day , total four cycle . The patient clinical benefit directly EL scheme first line treatment accept temozolomide maintenance therapy , 150mg / m2 , oral D1-5 . A period 28 day , regular follow-up evaluation effectiveness , safety quality life .</detailed_description>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>1. age 18 70 year old , men woman limit ; 2. confirm histopathological examination SCLC ; 3. clinical stage patient extensive stage ( except case pleural effusion ) 4. patient drug treatment history 5. implementation palliative radiotherapy metastatic lesion , surgical treatment , end treatment 14 day . 6. measured lesion ( non radiation exposure site ) patient ( RECIST ) evaluation ; 7. physical condition score ECOG PS:01 8. expect survival time 3 month 1. previous platinum compound history allergy ; 2. active ulcer patient ; 3 . Patients primary lung lesion treat radiotherapy ; 4. chest Xray show clear interstitial pneumonia patient pulmonary fibrosis ; 5. need treatment brain metastasis active phase 6. serious tumor invasion , superior vena cava syndrome , middle volume malignant pleural effusion , abdominal effusion pericardial effusion , yet control ; 7. serious infection , ADH abnormal secretion syndrome , poor control diabetes , need treatment patient severe complication vena cava syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>